

Original Article

Geospatial Analysis of Type C and B Hepatitis in South Sulawesi

Rini Rachmawarni Bachtiar¹, Andi Alfian Zainuddin², Rahmawati Minhajat¹, Sri Jayanti³

¹ Department of Internal Medicine, Faculty of Medicine, Hasanuddin University, Makassar, South Sulawesi, Indonesia

² Department of Public Health, Faculty of Medicine, Hasanuddin University, Makassar, South Sulawesi, Indonesia

³ Eijkman Research Center for Molecular Biology, National Research and Innovation Agency, Cibinong, Indonesia

Corresponding Author:

Name: Rini Rachmawarni Bachtiar

Email: doarini@gmail.com

ARTICLE INFO

Keywords:

Hepatitis B, Hepatitis C, Sporadic

How to cite:

Bachtiar, R.R., Zainuddin A.A., Minhajat, R., & Jayanti, S.. (2024). Geospatial Analysis of Type B and C Hepatitis in South Sulawesi. *Nusantara Medical Science Journal*, 9(1), 26–37.

DOI:

10.20956/nmsj.vi.34204

ABSTRACT

Introduction: Hepatitis C and B are two infectious diseases that increase distribution and high mortality and morbidity. Conditions that exacerbate the economic burden of these two viral hepatitis infections are complications of cirrhosis and gastrointestinal bleeding. This study sought to assess the risk levels of hepatitis C and B across various districts and cities in South Sulawesi. It involved identifying spatial clusters of affected individuals through an analytical model, employing Generalized Poisson Regression to evaluate the potential impacts of these viral infections. **Methods:** The natural break method is a quantifiable technique for identifying value clusters indicative of data distribution and for detecting geographical illness clusters, using Global Moran's I statistics. This research utilizes data from health insurance members diagnosed with hepatitis C and B between January 2020 and December 2022, including 24 districts and cities in South Sulawesi Province. **Results:** According to the results of the Local Morans I analysis, there is no significant clustered hepatitis C and B in all districts and cities in South Sulawesi from 2020 until 2022.

Conclusions: *In South Sulawesi, the incidence of hepatitis C and B cases reported to National Social Health Insurance Administration Body (BPJS Kesehatan) appeared to manifest randomly or sporadically.*

Copyright © 2024 NMSJ. All rights reserved.

1. INTRODUCTION

Infectious diseases are still a problem in current health development because of a significant burden on the health financing budget for managing diseases and complications.¹ Hepatitis C and B are infectious diseases that increase distribution mortality and morbidity.²⁻⁵ These viral hepatitis infections have more dangerous progression than other variants because most cases develop chronically and become hepatocellular carcinoma.⁶⁻⁹ Hepatitis B occurs in 3.5-5.6% of people worldwide in different age groups.¹⁰ Hepatitis C has happened in at least 1% of the world's population, around 71.1 million people, with an incidence reaching 23.7 people per 100,000 people.¹¹ Conditions that exacerbate the economic burden of these two viral hepatitis infections are complications of cirrhosis and gastrointestinal bleeding.¹²

Indonesia faces conditions of increasing non-communicable diseases, persistent infectious diseases, and new diseases.¹³ The increase in cases of hepatitis C and B in Indonesia occurs due to movement through drug abuse, intercourse, and in a small population of health workers.^{14,15} This increase in cases has increased the incidence of hepatocellular carcinoma and hepatic cirrhosis.^{16,17} Control of hepatitis C and B needs to be improved by preventing the transmission of these diseases through vaccination and exceptional infection control in at-risk populations. Control through immunization of hepatitis B reduces the incidence of complications and mortality. Control of at-risk populations for hepatitis C and B requires assistance from relevant agencies, especially control of infection through transfusion or health workers.¹⁸⁻²¹

Spatial analysis of the conditions of hepatitis C and B in South Sulawesi needs to be carried out to prevent the development of widespread cases so that steps can be taken to reduce the spread and complications. This analysis allows for predictions and the knowledge of the spatial variations of an area in the occurrence of certain diseases. An analysis model and generalized Poisson regression were utilized in this study to determine the potential effects of hepatitis C and B. The study's objective was to ascertain the risk level of hepatitis C and B in each district or city within the province of South Sulawesi. This was accomplished by identifying spatial clusters on the number of people who suffer from the disease.

2. METHODS

a. Ethics approval

The Ethics Committee of Medical Research at the Faculty of Medicine Hasanuddin University has reviewed and approved this study (109/UN4.6.4.5.31/PP36/2024). The Helsinki Declaration carried out this study. The Ethics Committee of Medical Research at Hasanuddin University's Faculty of Medicine has waived the requirement for informed consent. The dataset utilized in

this study was obtained from the National Social Health Insurance Administration Body (BPJS Kesehatan).

b. Study Area

South Sulawesi Province stands out as one of the Indonesian provinces characterized by a significant population density. In 2020, the population was approximately 9 million individuals, and the overall expanse encompassed approximately 46.717 km².




Figure 1. The map of research Area⁴⁷

c. Data Utilized

This study used data from health insurance members diagnosed with hepatitis C and B between January 2020 and December 2022 across 24 districts and cities in South Sulawesi Province. This research used districts and cities as the geographical units of analysis. The data was sourced from the Social Health Insurance Administration Body, a government agency responsible for managing Indonesian health insurance initiatives. Population information were sourced from the Central Bureau of information of South Sulawesi Province, known locally as Badan Pusat Statistik (BPS), a non-departmental governmental entity responsible for conducting statistical surveys in Indonesia. A monthly aggregation of daily health insurance participant data was performed, and prevalence rates were computed for 100,000 individuals. The daily statistics for hepatitis C and B were analyzed according to the prevalence rates of these infections.

The yearly prevalence rate was calculated, with the average for 2020–2022 being the mean of the rates for each district or city in 2020, 2021, and 2022.




Figure 3. Natural breaks of hepatitis C.

According to the results of the Local Morans I analysis, there was no significant clustering of hepatitis B (Figure 4 and Table 1) and C (Figure 5 and Table 1) in all districts and cities in South Sulawesi from 2020 until 2022.



Figure 4. Local Moran's Hepatitis B.




Figure 5. Local Moran's Hepatitis C.

Table 1. Local Moran's Hepatitis C and B

Variable	Global Moran's I	p-value	Conclusion
Hepatitis C	-0.039	0.451	Not significant
Hepatitis B	-0.061	0.693	Not significant

4. DISCUSSIONS

Hepatitis C and B are viral infections that can manifest acutely or chronically. Severe complications such as encephalopathy and gastrointestinal bleeding can occur, causing mortality.²²⁻²⁵ The spread of hepatitis C and B through contact with body fluids is sometimes not detected because someone is in the asymptomatic period or accidentally, so the spread occurs in at-risk populations.^{26,27} The development of hepatitis C and B in South Sulawesi 2020-2022 experienced fluctuations due to the COVID-19 outbreak.²⁸⁻³¹ Makassar is the area with the highest incidence as a referral center in South Sulawesi. This happens because diagnostic facilities are only available at advanced referral health facilities.

Hepatitis C and B also increased randomly, along with increases in oesophageal varices, hepatocellular carcinoma, and liver cirrhosis. This condition is by previous research, which shows that areas with a high prevalence of hepatitis C and B cause an increase in the incidence of oesophageal varices, liver cirrhosis, and hepatocellular carcinoma.^{24,32,33} This occurs due to the unique mechanism of chronic viral hepatitis, which can become hepatocellular carcinoma without going through the cirrhosis phase.

Although not absolute causes, hepatitis C and B significantly increase the incidence of complications of liver cirrhosis and hepatocellular carcinoma.^{25,34-36} The mechanism underlying the complications of esophageal varices and hepatocellular carcinoma is hepatocyte death, which induces fibrosis and damage to cellular antiapoptotic factors, which triggers excessive proliferation of abnormal hepatocytes that develop into cancer.³⁷⁻⁴⁰

The spread of hepatitis C and B is sporadic because most cases are cases of transmission from blood and body fluids.⁴¹⁻⁴³ The slower appearance of symptoms causes the detection of hepatitis C and B and its complications.⁴⁴⁻⁴⁶ Case findings in the earlier period were discovered incidentally and not due to chief complaints. Distribution data from BPJS Kesehatan does not provide a complete picture of sufferers because findings in examination cases without indications are not recorded. Policies related to vaccination and screening programs and increasing the use of BPJS Kesehatan evenly in South Sulawesi and Indonesia increase data collection on hepatitis C and B description.

According to the mechanism of transmission, hepatitis is an infectious disease that can spread from person to person. The most common ways for it to spread are through sexual contact, which can spread the disease through vaginal secretions, blood, and semen secretions, as well as through infectious external sources like tattoos, dialysis machines, unsanitary needles and razors, and the transfusion of infected human blood. This transmission of contagion is referred to as horizontal transmission. It is also possible for the virus to be vertically transferred from mother to infant at the time of birth. Hepatitis C and B are primarily transmitted via the parenteral route. Individuals above the age of 35 were found as a major risk factor for HCV and HBV transmission in a study conducted by⁵². Research indicates that individuals with detectable anti-HBc, regardless of the presence of anti-HBs and negative for HBsAg, may have modest levels of viremia.⁵⁰⁻⁵³

There are several challenges in detecting hepatitis C and B viruses to eliminate hepatitis. One of these challenges is the need for diagnostic tests for viral infections, especially in low- and middle-income countries. This remains a barrier to the target of hepatitis elimination by 2030. Although conventional diagnostic tests are available, they are largely inaccessible in low- and middle-income countries due to lack of competent personnel or high costs. This can result in poor linkage to care and increased infections. A thorough approach to hepatitis C and B surveillance, screening, immunization, and treatment might be the main emphasis of the public health strategy for both diseases.^{54,55}

5. CONCLUSION

This study conducted a geospatial analysis of patients with hepatitis C and B. In South Sulawesi, the cases of hepatitis C and B registered with BPJS Kesehatan appeared to be distributed randomly or sporadically, with no significant spatial clustering observed. This information can be valuable for policymakers in developing a comprehensive program aimed at reducing the prevalence of these diseases and mitigating the risks of complications such as esophageal varices bleeding and hepatocellular carcinoma.

ACKNOWLEDGMENTS

We acknowledge that this research is funded by Faculty of Medicine, Hasanuddin University.

REFERENCES

1. Colzani E. Beyond morbidity and mortality: the burden of infectious diseases on healthcare services. *Epidemiol Infect.* 2019;147:e251.
2. Blach S, Terrault NA, Tacke F, Gamkrelidze I, Craxi A, Tanaka J, et al. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study. *The Lancet Gastroenterology & Hepatology.* 2022;7(5):396–415.
3. Goel A, Seguy N, Aggarwal R. Burden of hepatitis C virus infection in India: a systematic review and meta-analysis. *Journal of gastroenterology and hepatology.* 2019;34(2):321–9.
4. Gomes C, Wong RJ, Gish RG. Global perspective on hepatitis B virus infections in the era of effective vaccines. *Clinics in liver disease.* 2019;23(3):383–99.
5. Sheena BS, Hiebert L, Han H, Ippolito H, Abbasi-Kangevari M, Abbasi-Kangevari Z, et al. Global, regional, and national burden of hepatitis B, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. *The Lancet Gastroenterology & Hepatology.* 2022;7(9):796–829.
6. Carrat F, Fontaine H, Dorival C, Simony M, Diallo A, Hezode C, et al. Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study. *The Lancet.* 2019;393(10179):1453–64.
7. Koffas A, Kennedy PT. Hepatitis B and D. *Medicine.* 2019;47(11):746–51.
8. Meringer H, Shibolet O, Deutsch L. Hepatocellular carcinoma in the post-hepatitis C virus era: Should we change the paradigm? *World journal of gastroenterology.* 2019;25(29):3929.
9. Sagnelli C, Sica A, Creta M, Calogero A, Ciccozzi M, Sagnelli E. Epidemiological and clinical aspects of hepatitis B virus infection in Italy over the last 50 years. *World Journal of Gastroenterology.* 2022;28(26):3081.
10. Schmit N, Nayagam S, Thursz MR, Hallett TB. The global burden of chronic hepatitis B virus infection: comparison of country-level prevalence estimates from four research groups. *International Journal of Epidemiology.* 2021;50(2):560–9.
11. Roudot-Thoraval F. Epidemiology of hepatitis C virus infection. *Clinics and Research in Hepatology and Gastroenterology.* 2021 May;45(3):101596.
12. Kanda T, Goto T, Hirotsu Y, Moriyama M, Omata M. Molecular mechanisms driving progression of liver cirrhosis towards hepatocellular carcinoma in chronic hepatitis

- B and C infections: a review. *International journal of molecular sciences*. 2019;20(6):1358.
13. Oktaria V, Mahendradhata Y. The health status of Indonesia's provinces: the double burden of diseases and inequality gap. *The Lancet Global Health*. 2022;10(11):e1547–8.
 14. Solomay T, Semenenko T. Viral hepatitis B, C and infectious mononucleosis: epidemiological similarities and differences. *Problems of Virology*. 2020;65(1):27–34.
 15. Stasi C, Silvestri C, Voller F. Update on hepatitis C epidemiology: unaware and untreated infected population could be the key to elimination. *SN comprehensive clinical medicine*. 2020;2:2808–15.
 16. Nam JY, Jang ES, Kim YS, Lee YJ, Kim IH, Cho SB, et al. Epidemiological and clinical characteristics of hepatitis C virus infection in South Korea from 2007 to 2017: a prospective multicenter cohort study. *Gut and Liver*. 2020;14(2):207.
 17. Tan M, Bhadoria AS, Cui F, Tan A, Van Holten J, Easterbrook P, et al. Estimating the proportion of people with chronic hepatitis B virus infection eligible for hepatitis B antiviral treatment worldwide: a systematic review and meta-analysis. *The Lancet Gastroenterology & Hepatology*. 2021;6(2):106–19.
 18. Flores JE, Thompson AJ, Ryan M, Howell J. The Global Impact of Hepatitis B Vaccination on Hepatocellular Carcinoma. *Vaccines*. 2022 May 17;10(5):793.
 19. Ghany MG, Morgan TR, AASLD-IDSAs Hepatitis C Guidance Panel. Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases–Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. *Hepatology*. 2020 Feb;71(2):686–721.
 20. Nguyen MH, Wong G, Gane E, Kao JH, Dusheiko G. Hepatitis B Virus: Advances in Prevention, Diagnosis, and Therapy. *Clin Microbiol Rev*. 2020 Mar 18;33(2):e00046-19.
 21. Ward JW, Hinman AR. What is needed to eliminate hepatitis B virus and hepatitis C virus as global health threats. *Gastroenterology*. 2019;156(2):297–310.
 22. Premkumar M, Anand AC. Overview of complications in cirrhosis. *Journal of Clinical and Experimental Hepatology*. 2022;
 23. Jaffe A, Lim JK, Jakab SS. Pathophysiology of hepatic encephalopathy. *Clinics in Liver Disease*. 2020;24(2):175–88.
 24. Weng W zhen, Chen J feng, Peng X hua, Huang M, Zhang J, Xiong J, et al. Risk factors for underlying comorbidities and complications in patients with hepatitis B virus-related acute-on-chronic liver failure. *Epidemiol Infect*. 2022;150:e147.

25. Zhao H, Wang Q, Luo C, Liu L, Xie W. Recompensation of decompensated hepatitis B cirrhosis: current status and challenges. *BioMed Research International*. 2020;2020.
26. Tanaka J, Akita T, Ko K, Miura Y, Satake M, Epidemiological Research Group on Viral Hepatitis and its Long-term Course, Ministry of Health, Labour and Welfare of Japan. Countermeasures against viral hepatitis B and C in Japan: An epidemiological point of view. *Hepatology Research*. 2019 Sep;49(9):990–1002.
27. Voulgaris T, Karagiannakis D, Siakavellas S, Kalogera D, Angelopoulos T, Chloupis E, et al. High prevalence of asymptomatic peptic ulcers diagnosed during screening endoscopy in patients with cirrhosis. *Annals of Gastroenterology*. 2019;32(5):451.
28. Rehman ST, Rehman H, Abid S. Impact of coronavirus disease 2019 on prevention and elimination strategies for hepatitis B and hepatitis C. *World Journal of Hepatology*. 2021;13(7):781.
29. Chen B, Wang M, Huang X, Xie M, Pan L, Liu H, et al. Changes in incidence of notifiable infectious diseases in China under the prevention and control measures of COVID-19. *Frontiers in public health*. 2021;9:728768.
30. Yan X, Wang X, Zhang X, Wang L, Zhang B, Jia Z. The epidemic of sexually transmitted diseases under the influence of COVID-19 in China. *Frontiers in public health*. 2021;9:737817.
31. Pley CM, McNaughton AL, Matthews PC, Lourenço J. The global impact of the COVID-19 pandemic on the prevention, diagnosis and treatment of hepatitis B virus (HBV) infection. *BMJ Global Health*. 2021;6(1):e004275.
32. Liu YB, Chen MK. Epidemiology of liver cirrhosis and associated complications: Current knowledge and future directions. *World J Gastroenterol*. 2022 Nov 7;28(41):5910–30.
33. Mantovani A, Tsochatzis EA. Epidemiology of varices and variceal bleeding in liver cirrhosis. *Variceal Bleeding in Liver Cirrhosis*. 2021;1–11.
34. Wang M, Li C, Liang L, Xing H, Sun L, Quan B, et al. Early and late recurrence of hepatitis B virus-associated hepatocellular carcinoma. *The oncologist*. 2020;25(10):e1541–51.
35. Alsahhar JS, Elwir S. Epidemiology and natural history of chronic liver disease. *The Critically Ill Cirrhotic Patient: Evaluation and Management*. 2020;1–9.
36. Trifan A. The risks of hepatocellular carcinoma and variceal bleeding after HCV eradication with direct-acting antiviral therapy: a propensity score analysis. *MSJ*. 2021 Mar 30;125(1):54–64.

37. Liu H, Sun J, Liu X, Liu G, Zhou Q, Deng J, et al. Dual-energy computed tomography for non-invasive prediction of the risk of oesophageal variceal bleeding with hepatitis B cirrhosis. *Abdom Radiol.* 2021 Nov;46(11):5190–200.
38. Alqahtani SA, Jang S. Pathophysiology and Management of Variceal Bleeding. *Drugs.* 2021 Apr;81(6):647–67.
39. Khatun M, Ray RB. Mechanisms underlying hepatitis C virus-associated hepatic fibrosis. *Cells.* 2019;8(10):1249.
40. Yue M. Unsolved challenges in hepatitis B and hepatitis C: from prevention to treatment. *Frontiers in Cellular and Infection Microbiology.* 2023;13.
41. Yuniastuti E, Ratih DM, Aisyah MR, Hidayah AJ, Widhani A, Sulaiman AS, et al. Needlestick and sharps injuries in an Indonesian tertiary teaching hospital from 2014 to 2017: a cohort study. *BMJ open.* 2020;10(12):e041494.
42. Guvenir M, Arikan A. Hepatitis B virus: from diagnosis to treatment. *Polish Journal of Microbiology.* 2020;69(4):391–9.
43. Atlaw D, Sahiledengle B, Tariku Z. Hepatitis B and C virus infection among healthcare workers in Africa: a systematic review and meta-analysis. *Environ Health Prev Med.* 2021 Dec;26(1):61.
44. Nguyen MH, Wong G, Gane E, Kao JH, Dusheiko G. Hepatitis B Virus: Advances in Prevention, Diagnosis, and Therapy. *Clin Microbiol Rev.* 2020 Mar 18;33(2):e00046-19.
45. Gholizadeh O, Akbarzadeh S, Ghazanfari Hashemi M, Gholami M, Amini P, Yekanipour Z, et al. Hepatitis A: viral structure, classification, life cycle, clinical symptoms, diagnosis error, and vaccination. *Canadian Journal of Infectious Diseases and Medical Microbiology.* 2023;2023.
46. Roger S, Ducancelle A, Le Guillou-Guillemette H, Gaudy C, Lunel F. HCV virology and diagnosis. *Clinics and Research in Hepatology and Gastroenterology.* 2021 May;45(3):101626.
47. Zainuddin AA, Rahim A, Ramadany S, et al. Geospatial analysis of type 2 diabetes mellitus and hypertension in South Sulawesi, Indonesia. *Sci Rep.* 2023;13(1). doi:10.1038/s41598-023-27902-y
48. Anselin L, Syabri I, Kho Y. GeoDa: An introduction to spatial data analysis. *Geogr Anal.* 2006;38(1):5-22. doi:10.1111/j.0016-7363.2005.00671.x
49. Abdulhafedh A. A Novel Hybrid Method for Measuring the Spatial Autocorrelation of Vehicular Crashes: Combining Moran's Index and Getis-Ord G_i^* .

- Statistic. *Open Journal of Civil Engineering*. 2017;07(02):208-221. doi:10.4236/ojce.2017.72013
50. Shenge JA, Osiowy C. Rapid Diagnostics for Hepatitis B and C Viruses in Low- and Middle-Income Countries. *Frontiers in Virology*. 2021;1. doi:10.3389/fviro.2021.742722
51. Mohsen A, Hattaf K, AL-Husseiny H. Dynamical Analysis of Transmission of Hepatitis B and C Viruses with External Source of disease by Mathematical Model. Published online September 7, 2021. doi:10.21203/rs.3.rs-730763/v1
52. Naqvi IH, Talib A, Baloch G, Mahmood K, Qadari Z. HEPATITIS B AND C: FREQUENCY, MODES OF TRANSMISSION AND RISK FACTORS ALONG WITH SOME UNORTHODOX ROUTES OF SPREAD. www.pjph.org
53. Ifeorah IM, Bakarey AS, Adewumi MO, et al. Patterns of serologic markers of hepatitis B virus infection and the risk of transmission among pregnant women in southwestern Nigeria. *J Immunoassay Immunochem*. 2017;38(6):639-651. doi:10.1080/15321819.2017.1384389
54. Cui F, Blach S, Manzengo Mingiedi C, et al. Global reporting of progress towards elimination of hepatitis B and hepatitis C. *Lancet Gastroenterol Hepatol*. 2023;8(4):332-342. doi:10.1016/S2468-1253(22)00386-7
55. Xu M, Terrault NA. Hepatitis B Virus Elimination Strategies. *Curr Hepatol Rep*. 2024;23(2):268-277. doi:10.1007/s11901-024-00658-3

Conflict of Interest Statement:

The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2024 NMSJ. All rights reserved.